The present invention relates to pharmaceutical preparation ARN-509, it can be applied to the mammal with androgen receptor (AR) related disease or illness, specifically people, the AR related diseases or illness specifically cancer, more specifically prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, without chemotherapy metastatic castration-resistant prostate cancer, biochemical recurrent hormone-sensitive prostate cancer or high risk non-metastatic castration-resistant prostate cancer. In one aspect, these preparations include the solid dispersions of ARN-509 and HPMCAS. In one aspect, the solid dispersions of ARN-509 and HPMCAS can obtain in the following way, obtain in particular by such as under type: melting extrusion includes the mixture of ARN-509 and HPMCAS and optionally then grinds the mixture of the melting extrusion. In one aspect, the solid dispersions of ARN-509 and HPMCAS can obtain in the following way, obtain in particular by such as under type: spray drying includes the mixture of the ARN-509 and HPMCAS that are dissolved in suitable solvent.
